IL138214A0
(en)
|
1998-03-09 |
2001-10-31 |
Zealand Pharmaceuticals As |
Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
SE9801571D0
(sv)
|
1998-05-05 |
1998-05-05 |
Wapharm Ab |
Melanokortin-1-receptorselektiva föreningar
|
US6444788B1
(en)
|
1999-03-15 |
2002-09-03 |
Novo Nordisk A/S |
Ion exchange chromatography of GLP-1, analogs and derivatives thereof
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
US7371721B2
(en)
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
DE60134251D1
(de)
|
2000-09-18 |
2008-07-10 |
Sanos Bioscience As |
Verwendung von glp-2-peptiden
|
MXPA03005135A
(es)
|
2000-12-13 |
2003-12-04 |
Lilly Co Eli |
Regimen de tratamiento cronico usando peptidos insulinotropicos similares al glucagon.
|
CN1162446C
(zh)
*
|
2001-05-10 |
2004-08-18 |
上海华谊生物技术有限公司 |
促胰岛素分泌肽衍生物
|
CN1158304C
(zh)
*
|
2001-05-10 |
2004-07-21 |
上海华谊生物技术有限公司 |
蛙皮抗菌肽衍生物
|
EP1412384B1
(en)
|
2001-06-28 |
2007-12-26 |
Novo Nordisk A/S |
Stable formulation of modified glp-1
|
JP2005501058A
(ja)
|
2001-07-31 |
2005-01-13 |
ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ |
Glp−1、exendin−4、そのペプチド・アナログ及びその使用
|
US8129504B2
(en)
|
2001-08-30 |
2012-03-06 |
Biorexis Technology, Inc. |
Oral delivery of modified transferrin fusion proteins
|
US7176278B2
(en)
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
EP2050460A1
(en)
|
2001-09-24 |
2009-04-22 |
Imperial Innovations Limited |
PYY and agonists thereof for modification of feeding behaviour
|
WO2003059378A2
(en)
|
2001-12-29 |
2003-07-24 |
Novo Nordisk A/S |
Combined use of a glp-1 compound and another drug for treating dyslipidemia
|
JP4733922B2
(ja)
|
2002-01-10 |
2011-07-27 |
インペリアル・イノベ−ションズ・リミテッド |
摂食行動の修正
|
US7105489B2
(en)
*
|
2002-01-22 |
2006-09-12 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treating polycystic ovary syndrome
|
EP1494704A1
(en)
*
|
2002-04-04 |
2005-01-12 |
Novo Nordisk A/S |
Glp-1 agonist and cardiovascular complications
|
CA2490564A1
(en)
*
|
2002-07-04 |
2004-01-15 |
Zealand Pharma A/S |
Glp-1 and methods for treating diabetes
|
JP2006501820A
(ja)
*
|
2002-09-06 |
2006-01-19 |
バイエル・フアーマシユーチカルズ・コーポレーシヨン |
修飾glp−1受容体アゴニストおよびそれらの薬理学的使用法
|
US7273921B2
(en)
|
2002-09-25 |
2007-09-25 |
Novo Nordisk A/S |
Method for producing acylated peptides
|
BR0314996A
(pt)
|
2002-10-02 |
2005-08-09 |
Zealand Pharma As |
Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
|
CA2502118A1
(en)
*
|
2002-10-11 |
2004-05-06 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
Glp-1 derivatives and transmicosal absorption preparations thereof
|
US6818721B2
(en)
|
2002-12-02 |
2004-11-16 |
Rpo Pty Ltd. |
Process for producing polysiloxanes and use of the same
|
EP1688148A1
(en)
*
|
2002-12-03 |
2006-08-09 |
Novo Nordisk A/S |
Combination treatment using exendin-4 and thiazolidinediones
|
EP1569682A2
(en)
*
|
2002-12-03 |
2005-09-07 |
Novo Nordisk A/S |
Combination treatment using exendin-4 and thiazolidinediones
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
EP1626981A4
(en)
*
|
2003-03-04 |
2006-11-22 |
Biorexis Pharmaceutical Corp |
PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE
|
DE10314610A1
(de)
|
2003-04-01 |
2004-11-04 |
Aventis Pharma Deutschland Gmbh |
Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
|
US8008255B2
(en)
|
2003-05-30 |
2011-08-30 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for enhanced transmucosal delivery of peptides and proteins
|
US7008957B2
(en)
|
2003-07-25 |
2006-03-07 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
|
US7094800B2
(en)
|
2003-07-25 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Cyanopyrrolidides, process for their preparation and their use as medicaments
|
US7094794B2
(en)
|
2003-07-28 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
|
DE10335092B3
(de)
|
2003-08-01 |
2005-02-03 |
Aventis Pharma Deutschland Gmbh |
Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
|
TW200522976A
(en)
|
2003-09-19 |
2005-07-16 |
Novo Nordisk As |
Novel plasma protein affinity tags
|
EP2932981B1
(en)
*
|
2003-09-19 |
2021-06-16 |
Novo Nordisk A/S |
Albumin-binding derivatives of GLP-1
|
CN100444898C
(zh)
*
|
2003-09-19 |
2008-12-24 |
诺沃挪第克公司 |
治疗肽的清蛋白结合型衍生物
|
WO2005046716A1
(en)
*
|
2003-11-13 |
2005-05-26 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia
|
US20060287221A1
(en)
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
CN104826116A
(zh)
|
2003-11-20 |
2015-08-12 |
诺沃挪第克公司 |
对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
|
ATE498404T1
(de)
|
2003-12-09 |
2011-03-15 |
Novo Nordisk As |
Regulierung der nahrungspräferenz mit glp-1- agonisten
|
CA2550217A1
(en)
*
|
2003-12-12 |
2005-07-07 |
Michael A. Brownlee |
Glp-1 (9-36) methods and compositions
|
MXPA06006745A
(es)
|
2003-12-18 |
2006-08-18 |
Novo Nordisk As |
Compuestos glp-1 novedosos.
|
WO2005077072A2
(en)
|
2004-02-11 |
2005-08-25 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
CN1318587C
(zh)
*
|
2004-04-30 |
2007-05-30 |
成都芝田生物工程有限公司 |
酰胺化Exendin-4多肽的重组制备方法
|
US8410047B2
(en)
|
2004-06-11 |
2013-04-02 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using GLP-1 agonists
|
DE102004043153B4
(de)
*
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
AU2012202855B2
(en)
*
|
2004-09-03 |
2015-02-26 |
Philipps-Universitat Marburg |
GLP-1 and exendin related invention
|
US8030273B2
(en)
|
2004-10-07 |
2011-10-04 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
EP1799710A2
(en)
|
2004-10-07 |
2007-06-27 |
Novo Nordisk A/S |
Protracted glp-1 compounds
|
US20090011976A1
(en)
*
|
2004-11-12 |
2009-01-08 |
Novo Nordisk A/S |
Stable Formulations Of Peptides
|
DE102004058306A1
(de)
*
|
2004-12-01 |
2006-07-27 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
|
US8716221B2
(en)
|
2005-01-14 |
2014-05-06 |
Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. |
Modified exendins and uses thereof
|
EP2505207B1
(en)
|
2005-01-14 |
2015-04-22 |
Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. |
Modified exendins and uses thereof
|
EP2390264A1
(en)
|
2005-02-11 |
2011-11-30 |
Amylin Pharmaceuticals Inc. |
GIP analog and hybrid polypeptides with selectable propperties
|
WO2007022123A2
(en)
|
2005-08-11 |
2007-02-22 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
JP2008531730A
(ja)
|
2005-03-04 |
2008-08-14 |
キュアーディーエム、インク. |
I型真性糖尿病及び他の症状を治療するための方法及び薬学的組成物
|
WO2006097535A2
(en)
*
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
TWI362392B
(en)
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
JP5755398B2
(ja)
*
|
2005-03-18 |
2015-07-29 |
ノヴォ ノルディスク アー/エス |
伸長されたglp−1化合物
|
EP2295452A1
(en)
|
2005-05-04 |
2011-03-16 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (GLP-2) analogues
|
US7393919B2
(en)
|
2005-05-25 |
2008-07-01 |
Cure Dm, Inc. |
Peptides, derivatives and analogs thereof, and methods of using same
|
BRPI0614649A2
(pt)
|
2005-08-11 |
2011-04-12 |
Amylin Pharmaceuticals Inc |
polipeptìdeos hìbridos com propriedades selecionáveis
|
DK1919947T3
(da)
|
2005-08-26 |
2013-03-18 |
Abbvie Inc |
Terapeutisk aktive alfa-MSH analoger
|
DE102006031955A1
(de)
|
2006-07-11 |
2008-01-17 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
|
DE102006031962A1
(de)
|
2006-07-11 |
2008-01-17 |
Sanofi-Aventis Deutschland Gmbh |
Amidiertes Insulin Glargin
|
CN101511868B
(zh)
|
2006-07-24 |
2013-03-06 |
比奥雷克西斯制药公司 |
毒蜥外泌肽融合蛋白
|
RU2009108280A
(ru)
|
2006-08-08 |
2010-09-20 |
Санофи-Авентис (Fr) |
Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
|
US20100179131A1
(en)
|
2006-09-07 |
2010-07-15 |
Nycomed Gmbh |
Combination treatment for diabetes mellitus
|
EA023886B1
(ru)
|
2006-11-08 |
2016-07-29 |
Зеаланд Фарма А/С |
Селективные аналоги глюкагонподобного пептида-2 (glp-2)
|
JP2010043001A
(ja)
*
|
2006-11-09 |
2010-02-25 |
Sanwa Kagaku Kenkyusho Co Ltd |
Glp−1誘導体とその用途
|
WO2008064306A2
(en)
|
2006-11-22 |
2008-05-29 |
Curedm, Inc. |
Methods and compositions relating to islet cell neogenesis
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
RU2413528C2
(ru)
|
2007-01-18 |
2011-03-10 |
Открытое Акционерное Общество "Валента Фармацевтика" |
Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
|
DE102007005045B4
(de)
|
2007-01-26 |
2008-12-18 |
Sanofi-Aventis |
Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
WO2008098693A2
(en)
*
|
2007-02-16 |
2008-08-21 |
Bayer Healthcare Ag |
Convergent synthesis of glp-1
|
PT2152663E
(pt)
|
2007-06-04 |
2014-06-03 |
Univ Ben Gurion |
Compostos de triarilo e composições que compreendem os mesmos
|
ATE520714T1
(de)
|
2007-06-15 |
2011-09-15 |
Zealand Pharma As |
Glucagonanaloga
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
NZ599756A
(en)
|
2007-08-30 |
2013-09-27 |
Curedm Group Holdings Llc |
Compositions and methods of using proislet peptides and analogs thereof
|
EP2190873B1
(en)
|
2007-09-05 |
2015-07-22 |
Novo Nordisk A/S |
Truncated glp-1 derivatives and their therapeutical use
|
EP2679597A1
(en)
|
2007-09-05 |
2014-01-01 |
Novo Nordisk A/S |
Glucagon-like peptide-1 derivatives and their pharmaceutical use
|
CA2703113A1
(en)
|
2007-10-27 |
2009-04-30 |
F. Hoffmann-La Roche Ag |
Insulinotropic peptide synthesis using solid and solution phase combination techniques
|
DE102007054497B3
(de)
|
2007-11-13 |
2009-07-23 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
|
JP5241849B2
(ja)
|
2007-11-16 |
2013-07-17 |
ノボ・ノルデイスク・エー/エス |
インスリン及びインスリン分泌性ペプチドを含む薬学的組成物
|
DE102008003566A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
DE102008025008A1
(de)
|
2008-05-24 |
2009-11-26 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
RU2524423C2
(ru)
|
2008-01-09 |
2014-07-27 |
Санофи-Авентис Дойчланд Гмбх |
Новые производные инсулина с чрезвычайно замедленным профилем время/действие
|
DE102008025007A1
(de)
|
2008-05-24 |
2009-11-26 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
NZ586589A
(en)
|
2008-01-09 |
2012-04-27 |
Sanofi Aventis Deutschland |
Novel insulin analogues having an extremely delayed time-action profile
|
DE102008003568A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
SG192405A1
(en)
*
|
2008-06-17 |
2013-08-30 |
Univ Indiana Res & Tech Corp |
Gip-based mixed agonists for treatment of metabolic disorders and obesity
|
CA2953975C
(en)
|
2008-06-27 |
2019-11-26 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
WO2010003624A2
(en)
|
2008-07-09 |
2010-01-14 |
Sanofi-Aventis |
Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
|
CN102112157B
(zh)
|
2008-08-06 |
2013-05-29 |
诺沃-诺迪斯克保健股份有限公司 |
具有延长的体内效能的缀合蛋白
|
DE102009038210A1
(de)
|
2009-08-20 |
2011-03-03 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
ES2650621T3
(es)
|
2008-10-17 |
2018-01-19 |
Sanofi-Aventis Deutschland Gmbh |
Combinación de una insulina y un agonista de GLP-1
|
DE102008053048A1
(de)
|
2008-10-24 |
2010-04-29 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
DE102008051834A1
(de)
|
2008-10-17 |
2010-04-22 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
EP2344519B1
(en)
|
2008-11-07 |
2016-09-28 |
The General Hospital Corporation |
C-terminal fragments of glucagon-like peptide-1 (glp-1)
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
PL2373681T3
(pl)
*
|
2008-12-10 |
2017-07-31 |
Glaxosmithkline Llc |
Kompozycje farmaceutyczne albiglutydu
|
PL2370460T3
(pl)
|
2008-12-15 |
2014-09-30 |
Zealand Pharma As |
Analogi glukagonu
|
CN102292348B
(zh)
|
2008-12-15 |
2015-07-08 |
西兰制药公司 |
胰高血糖素类似物
|
CA2747155A1
(en)
|
2008-12-15 |
2010-06-24 |
Zealand Pharma A/S |
Glucagon analogues
|
KR20110126589A
(ko)
|
2008-12-15 |
2011-11-23 |
질랜드 파마 에이/에스 |
글루카곤 유사체
|
TWI504405B
(zh)
|
2009-01-22 |
2015-10-21 |
Novo Nordisk Healthcare Ag |
穩定的生長激素化合物
|
WO2011003823A1
(de)
*
|
2009-07-06 |
2011-01-13 |
Sanofi-Aventis Deutschland Gmbh |
Langsamwirkende insulinzubereitungen
|
CN107080836A
(zh)
*
|
2009-07-06 |
2017-08-22 |
赛诺菲-安万特德国有限公司 |
含有甲硫氨酸的水性胰岛素制备物
|
AP3329A
(en)
|
2009-07-13 |
2015-06-30 |
Zealand Pharma As |
Acylated glucagon analogues
|
CN101987868B
(zh)
*
|
2009-07-30 |
2013-09-04 |
江苏豪森医药集团有限公司 |
Glp-1类似物的衍生物或其可药用盐和用途
|
WO2011015649A1
(en)
|
2009-08-06 |
2011-02-10 |
Novo Nordisk Health Care Ag |
Growth hormones with prolonged in-vivo efficacy
|
WO2011023754A1
(en)
|
2009-08-26 |
2011-03-03 |
Sanofi-Aventis |
Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
|
US20120264685A1
(en)
|
2009-10-22 |
2012-10-18 |
Rajesh Bahekar |
Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist
|
PL2324853T3
(pl)
|
2009-11-13 |
2016-01-29 |
Sanofi Aventis Deutschland |
Liksysenatyd jako dodatek do metforminy w leczeniu cukrzycy typu 2
|
AU2009238272B2
(en)
*
|
2009-11-13 |
2014-05-08 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to metformin
|
PE20121362A1
(es)
|
2009-11-13 |
2012-10-17 |
Sanofi Aventis Deutschland |
Composicion farmaceutica que comprende despro36exendina-4(1-39)-lys6-nh2, insulina gly(a21)-arg(b31)-arg(b32) y metionina
|
TWI468171B
(zh)
|
2009-11-13 |
2015-01-11 |
Sanofi Aventis Deutschland |
含glp-1激動劑及甲硫胺酸之醫藥組成物
|
DK2329848T4
(da)
|
2009-11-13 |
2019-09-09 |
Sanofi Aventis Deutschland |
Lixisenatid som supplerende behandling til insulin glargin og metformin til behandling af type 2-diabetes
|
DE102010011919A1
(de)
|
2010-03-18 |
2011-09-22 |
Sanofi-Aventis Deutschland Gmbh |
Pharmazeutische Zusammensetzung umfassend einen GLP-1-Agonisten und Methionin
|
JP2011105609A
(ja)
*
|
2009-11-13 |
2011-06-02 |
Sanofi-Aventis Deutschland Gmbh |
メトホルミンへの付加療法を含む2型糖尿病の治療方法
|
CN102892425A
(zh)
|
2010-01-20 |
2013-01-23 |
西兰制药公司 |
心脏病症的治疗
|
BR112012018116B1
(pt)
|
2010-01-22 |
2022-06-21 |
Novo Nordisk Health Care Ag |
Conjugados de hormônio do crescimento com eficácia in vivo prolongada
|
AU2011208620B2
(en)
|
2010-01-22 |
2015-04-16 |
Novo Nordisk Health Care Ag |
Stable growth hormone compounds
|
EP2542565A1
(en)
|
2010-03-01 |
2013-01-09 |
Novo Nordisk A/S |
Preparative rp-hplc method for purifying peptides
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
WO2011123943A1
(en)
|
2010-04-09 |
2011-10-13 |
Mount Sinai Hospital |
Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
|
DE102010015123A1
(de)
|
2010-04-16 |
2011-10-20 |
Sanofi-Aventis Deutschland Gmbh |
Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
CN103003300B
(zh)
|
2010-04-27 |
2017-06-09 |
西兰制药公司 |
Glp‑1受体激动剂和胃泌素的肽缀合物及其用途
|
US8691763B2
(en)
|
2010-05-04 |
2014-04-08 |
Glaxosmithkline Llc |
Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
EP2389945A1
(en)
|
2010-05-28 |
2011-11-30 |
Sanofi-Aventis Deutschland GmbH |
Pharmaceutical composition comprising AVE0010 and insulin glargine
|
CN101891823B
(zh)
*
|
2010-06-11 |
2012-10-03 |
北京东方百泰生物科技有限公司 |
一种Exendin-4及其类似物融合蛋白
|
EP2582709B1
(de)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
UY33462A
(es)
|
2010-06-23 |
2012-01-31 |
Zealand Pharma As |
Analogos de glucagon
|
AP2013006671A0
(en)
|
2010-06-24 |
2013-01-31 |
Zealand Pharma As |
Glucagon analogues
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
RU2546520C2
(ru)
|
2010-08-30 |
2015-04-10 |
Санофи-Авентис Дойчланд Гмбх |
Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
|
WO2012061466A2
(en)
|
2010-11-02 |
2012-05-10 |
The General Hospital Corporation |
Methods for treating steatotic disease
|
BR112013014942B1
(pt)
|
2010-12-16 |
2020-01-28 |
Novo Nordisk As |
composições sólidas para administração, e seus usos
|
TW201236692A
(en)
|
2011-02-02 |
2012-09-16 |
Sanofi Aventis Deutschland |
Prevention of hypoglycaemia in diabetes mellitus type 2 patients
|
EP2683702B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US8895547B2
(en)
|
2011-03-08 |
2014-11-25 |
Sanofi |
Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
US8901114B2
(en)
|
2011-03-08 |
2014-12-02 |
Sanofi |
Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
|
EP2683699B1
(de)
|
2011-03-08 |
2015-06-24 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
WO2012120051A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
EP2683704B1
(de)
|
2011-03-08 |
2014-12-17 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
WO2012120054A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
EP2683701B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
US20120277147A1
(en)
|
2011-03-29 |
2012-11-01 |
Sanofi-Aventis Deutschland Gmbh |
Prevention of hypoglycaemia in diabetes mellitus type 2 patients
|
ES2612278T3
(es)
|
2011-04-12 |
2017-05-16 |
Novo Nordisk A/S |
Derivados de GLP-1 doble-acilados
|
JP6442284B2
(ja)
|
2011-05-13 |
2018-12-19 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
2型糖尿病の処置のためのリキシセナチド及びメトホルミン
|
US20130040878A1
(en)
|
2011-05-13 |
2013-02-14 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for use in the treatment of diabetes type 2 patients
|
US8735349B2
(en)
|
2011-05-13 |
2014-05-27 |
Sanofi-Aventis Deutschland Gmbh |
Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
WO2013006692A2
(en)
|
2011-07-06 |
2013-01-10 |
The General Hospital Corporation |
Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
|
CN103917241A
(zh)
|
2011-08-29 |
2014-07-09 |
赛诺菲-安万特德国有限公司 |
用于2型糖尿病患者中的血糖控制的药物组合
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
US20130096060A1
(en)
|
2011-10-04 |
2013-04-18 |
Jens Stechl |
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the pancreatic duct system
|
WO2013050378A1
(en)
|
2011-10-04 |
2013-04-11 |
Sanofi-Aventis Deutschland Gmbh |
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
|
BR112014010200A2
(pt)
|
2011-10-28 |
2020-10-27 |
Sanofi-Aventis Deutschland Gmbh |
combinação farmacêutica, bem como seu uso na preparação de um medicamento para o tratamento de diabetes tipo 2
|
MX2014005351A
(es)
|
2011-11-03 |
2014-05-28 |
Zealand Pharma As |
Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
|
CN103087174B
(zh)
*
|
2011-11-03 |
2015-11-18 |
华东师范大学 |
一种glp-1衍生物dlg3312及其固相化学合成方法
|
JP2015500823A
(ja)
|
2011-12-09 |
2015-01-08 |
ノヴォ ノルディスク アー/エス |
Glp−1アゴニスト
|
AP2014007797A0
(en)
|
2011-12-23 |
2014-07-31 |
Boehringer Ingelheim Int |
Glucagon analogues
|
KR102072202B1
(ko)
|
2012-03-22 |
2020-01-31 |
노보 노르디스크 에이/에스 |
Glp-1 펩티드의 조성물 및 그것의 제조
|
HUE042757T2
(hu)
|
2012-03-22 |
2019-07-29 |
Novo Nordisk As |
Szállító szert tartalmazó készítmények és elõállításuk
|
TR201802689T4
(tr)
|
2012-05-03 |
2018-03-21 |
Zealand Pharma As |
Glukagon benzeri peptit-2 (glp-2) analogları.
|
AR090937A1
(es)
|
2012-05-03 |
2014-12-17 |
Zealand Pharma As |
Compuestos agonista duales de gip-glp-1 y metodos para usarlos
|
ES2871328T3
(es)
|
2012-06-20 |
2021-10-28 |
Novo Nordisk As |
Formulación de comprimido que comprende un péptido y un agente de suministro
|
CN109456400A
(zh)
|
2012-07-23 |
2019-03-12 |
西兰制药公司 |
胰高血糖素类似物
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
EP2911655A1
(en)
|
2012-10-24 |
2015-09-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tpl2 kinase inhibitors for preventing or treating diabetes and for promoting -cell survival
|
WO2014077575A1
(ko)
*
|
2012-11-13 |
2014-05-22 |
다인바이오 주식회사 |
덱에이 효소반응으로 조제한 항비만 및 항당뇨 효능을 갖는 한천 유래 네오아가로올리고당 복합 조성물
|
KR20140088837A
(ko)
*
|
2013-01-03 |
2014-07-11 |
한미약품 주식회사 |
N-말단 전하가 변형된 인슐린 분비 펩티드 유도체
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
HUE042381T2
(hu)
|
2013-04-03 |
2019-06-28 |
Sanofi Sa |
Cukorbetegség kezelése hosszan ható inzulinkészítményekkel
|
WO2014166836A1
(en)
|
2013-04-05 |
2014-10-16 |
Novo Nordisk A/S |
Growth hormone compound formulation
|
EP3016975B1
(en)
*
|
2013-07-04 |
2019-01-16 |
Novo Nordisk A/S |
Derivatives of glp-1 like peptides, and uses thereof
|
GB201315335D0
(en)
|
2013-08-29 |
2013-10-09 |
Of Singapore |
Amino diacids containing peptide modifiers
|
PT3057984T
(pt)
|
2013-10-17 |
2018-10-24 |
Boehringer Ingelheim Int |
Análogos de glucagon acilados
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
JP6657101B2
(ja)
|
2013-11-05 |
2020-03-04 |
ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ |
糖尿病及びそれから生じる疾患合併症の治療のための化合物
|
CA2929107C
(en)
|
2013-11-06 |
2023-09-26 |
Zealand Pharma A/S |
Glucagon-glp-1-gip triple agonist compounds
|
CN105849122B
(zh)
|
2013-11-06 |
2021-04-30 |
西兰制药公司 |
Gip-glp-1双重激动剂化合物及方法
|
CN103613657B
(zh)
*
|
2013-11-28 |
2016-01-13 |
孙玉琨 |
缩短肽链的Exendin4及其基因工程应用
|
RU2016132342A
(ru)
|
2014-01-09 |
2018-02-14 |
Санофи |
Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных
|
MX2016008978A
(es)
|
2014-01-09 |
2016-10-04 |
Sanofi Sa |
Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
|
SG11201604706TA
(en)
|
2014-01-09 |
2016-07-28 |
Sanofi Sa |
Stabilized pharmaceutical formulations of insulin aspart
|
KR101768446B1
(ko)
*
|
2014-03-21 |
2017-08-17 |
애니젠 주식회사 |
신규한 엑세나타이드 유사체 및 그의 용도
|
EP3985016A1
(en)
|
2014-10-29 |
2022-04-20 |
Zealand Pharma A/S |
Gip agonist compounds and methods
|
RS64300B1
(sr)
|
2014-12-12 |
2023-07-31 |
Sanofi Aventis Deutschland |
Formulacija fiksnog odnosa insulin glargina/liksisenatida
|
US20160235818A1
(en)
|
2015-01-16 |
2016-08-18 |
Sanofi-Aventis Deutschland Gmbh |
Treatment of Pediatric Type 2 Diabetes Mellitus Patients
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
ES2805743T3
(es)
|
2015-03-24 |
2021-02-15 |
Inst Nat Sante Rech Med |
Método y composición farmacéutica para uso en el tratamiento de la diabetes
|
US10336802B2
(en)
|
2015-04-16 |
2019-07-02 |
Zealand Pharma A/S |
Acylated glucagon analogue
|
BR112019010624A2
(pt)
|
2016-12-09 |
2019-10-22 |
Zealand Pharma As |
agonistas duplos de glp-1/glp-2 acilados e composição
|
TWI791539B
(zh)
|
2017-06-16 |
2023-02-11 |
丹麥商西蘭製藥公司 |
用於投予類升糖素胜肽-2(glp-2)類似物的給藥方案
|
FR3082426A1
(fr)
|
2018-06-14 |
2019-12-20 |
Adocia |
Compositions sous forme d'une solution aqueuse injectable comprenant au moins de l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
|
CN110996905A
(zh)
|
2017-07-27 |
2020-04-10 |
阿道恰公司 |
至少包含人胰岛素a21g和餐时作用胰高血糖素抑制剂的可注射水溶液形式的组合物
|
PE20211202A1
(es)
|
2017-08-24 |
2021-07-05 |
Novo Nordisk As |
Composiciones de glp-1 y sus usos
|
PL3746111T3
(pl)
|
2018-02-02 |
2024-01-15 |
Novo Nordisk A/S |
Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
|
EP3774837A1
(en)
|
2018-04-10 |
2021-02-17 |
Sanofi-Aventis Deutschland GmbH |
Method for cleavage of solid phase-bound peptides from the solid phase
|
CA3096495A1
(en)
|
2018-04-10 |
2019-10-17 |
Sanofi-Aventis Deutschland Gmbh |
Lixisenatide synthesis with capping
|
FR3083700B1
(fr)
|
2018-07-13 |
2021-03-12 |
Adocia |
Formulation thermostable d'insuline humaine a21g
|
EP3628683A1
(en)
|
2018-09-28 |
2020-04-01 |
Zealand Pharma A/S |
Formulations of glucagon-like-peptide-2 (glp-2) analogues
|
EP3628682A1
(en)
|
2018-09-28 |
2020-04-01 |
Zealand Pharma A/S |
Formulations of glucagon-like-peptide-2 (glp-2) analogues
|
TWI799680B
(zh)
*
|
2019-01-29 |
2023-04-21 |
美商美國禮來大藥廠 |
製備gip/glp1雙重促效劑之方法
|
CN109721653B
(zh)
*
|
2019-03-05 |
2023-02-03 |
嘉兴学院 |
一种胰高血糖素样肽-1片段类似物及其应用
|
US20210093698A1
(en)
|
2019-09-13 |
2021-04-01 |
Sanofi |
Treatment of type 2 diabetes mellitus
|
EP3858373A1
(en)
|
2020-01-31 |
2021-08-04 |
Adocia |
Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
|
PE20221575A1
(es)
|
2020-02-18 |
2022-10-06 |
Novo Nordisk As |
Formulaciones farmaceuticas
|
EP3915571A1
(en)
|
2020-05-29 |
2021-12-01 |
Adocia |
Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
|
EP3915572A1
(en)
|
2020-05-29 |
2021-12-01 |
Adocia |
Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
|
KR20230125802A
(ko)
*
|
2020-12-11 |
2023-08-29 |
아이피2아이피오 이노베이션스 리미티드 |
신규 화합물
|
EP4129324A1
(en)
|
2021-08-02 |
2023-02-08 |
Adocia |
Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
|
WO2023036862A1
(en)
|
2021-09-10 |
2023-03-16 |
Zealand Pharma A/S |
Process for formulating compositions comprising glucagon-like-peptide-2 (glp-2) analogues
|
WO2023118416A1
(en)
|
2021-12-23 |
2023-06-29 |
Zealand Pharma A/S |
Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues
|
WO2024068848A1
(en)
|
2022-09-28 |
2024-04-04 |
Zealand Pharma A/S |
Methods for treating obesity
|